{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:03:08Z","timestamp":1790197388038,"version":"4.1.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdcr.2026.05.073","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:29:14Z","timestamp":1784042954000},"page":"191-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stapokibart, a novel monoclonal antibody targeting the interleukin 4 receptor \u03b1 subunit: Promising results in a retrospective cohort of patients with bullous pemphigoid"],"prefix":"10.1016","volume":"76","author":[{"given":"Shufen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxue","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaguang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-7471","authenticated-orcid":false,"given":"Sijian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.05.073_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.jdcr.2026.05.073_bib2","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1007\/s12325-024-02992-w","article-title":"Pathophysiology of bullous pemphigoid: role of type 2 inflammation and emerging treatment strategies (narrative review)","volume":"41","author":"Werth","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdcr.2026.05.073_bib3","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jdcr.2026.05.073_bib4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.05.073_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.abd.2024.08.008","article-title":"Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis","volume":"100","author":"da Silva","year":"2025","journal-title":"An Bras Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2026.05.073_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.jdcr.2026.05.073_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:22:54Z","timestamp":1790194974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626004261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":7,"alternative-id":["S2352512626004261"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.073","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stapokibart, a novel monoclonal antibody targeting the interleukin 4 receptor \u03b1 subunit: Promising results in a retrospective cohort of patients with bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}